TOKYO (Reuters) – A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc , failed to get a proposal passed at the drugmaker’s annual general meeting (AGM) on Thursday.